Valneva SE (XPAR:VLA) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:VLA Valneva SE XPAR:VLA
59 GF Score
Price €2.90
GF Value €2.30
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Valneva SE Defensive Interval Ratio?

XPAR:VLA
59GF Score
Valneva SE XPAR:VLA
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Valneva SE (XPAR:VLA) Overvalued in 2026?

Based on GuruFocus' analysis, Valneva SE stock appears to be overvalued. The current stock price of €2.90 is trading 26.1% above its estimated GF Value™ of €2.30. GuruFocus considers Valneva SE to be Modestly Overvalued.

Key valuation signals for XPAR:VLA:

  • Defensive Interval Ratio:
  • GF Value™: €2.30 vs. price of €2.90 (26.1% above fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the XPAR:VLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valneva SE Business Description

Address 12 ter Quai Perrache, Bureaux Convergence, Bat. A, Ilot Saint-Joseph, Lyon, FRA, 69002
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
59GF Score

Get the complete analysis for XPAR:VLA

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.90
Price
€2.30
GF Value